Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nyxoah (NYXH)
NASDAQ:NYXH
Holding NYXH?
Track your performance easily
NYXH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.00 - $20.00
Previous Close$8.21
Volume13.55K
Average Volume (3M)66.24K
Market Cap
$283.35M
Enterprise Value$271.59M
Total Cash (Recent Filing)$21.61M
Total Debt (Recent Filing)$12.34M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Mar 13, 2025EPS Estimate
-$0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding28,660,000
10 Day Avg. Volume27,774
30 Day Avg. Volume66,240
Standard Deviation0.26
R-Squared0.08
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.03
Price to Sales (P/S)98.71
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue243.14
Enterprise Value/Gross Profit100.89
Enterprise Value/Ebitda-34.49
Forecast
1Y Price Target
$15.46Price Target Upside86.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Nyxoah News
PremiumCompany Announcements
Nyxoah to Present at Healthcare Conference Amidst Growth
PremiumCompany Announcements
Nyxoah’s Voting Rights Shift with ResMed Stake
PremiumCompany Announcements
Nyxoah SA Reports Growth Amid Clinical Advances
PremiumCompany Announcements
Nyxoah Eyes Strong US Launch Amid Financial Growth
PremiumCompany Announcements
Nyxoah Strengthens Leadership for U.S. and Global Expansion
PremiumCompany Announcements
Nyxoah to Announce Q3 2024 Financial ResultsBulls Say, Bears Say
Bulls Say
Financial HealthNyxoah reported a proforma cash position of €95.6M, indicating strong financial health.
Market OpportunityNyxoah estimates the target market for Genio in the U.S. is approximately 510,000 patients, representing an annual total addressable market in the U.S. of approximately $10 billion.
Product EffectivenessGenio resulted in a clinically meaningful 71.0% median reduction in Apnea Hypopnea Index (AHI) while sleeping supine at 12 months compared with baseline.
Bears Say
Market ExpansionThe European market is expected to continue being difficult to grow and penetrate, which may limit expansion opportunities.
Overall RisksMultiple risks including commercial, regulatory, development, manufacturing, financial, and liability are identified.
Share DilutionThe price target is being lowered due to share count dilution associated with the raise.
---
Ownership Overview
11.80%
Insiders
5.25% Mutual Funds
1.42% Other Institutional Investors
81.50% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
NYXH FAQ
What was Nyxoah’s price range in the past 12 months?
Nyxoah lowest stock price was $4.00 and its highest was $20.00 in the past 12 months.
What is Nyxoah’s market cap?
Currently, no data Available
When is Nyxoah’s upcoming earnings report date?
Nyxoah’s upcoming earnings report date is Mar 13, 2025 which is in 111 days.
How were Nyxoah’s earnings last quarter?
Nyxoah released its earnings results on Nov 06, 2024. The company reported -$0.526 earnings per share for the quarter, missing the consensus estimate of -$0.481 by -$0.045.
Is Nyxoah overvalued?
According to Wall Street analysts Nyxoah’s price is currently Undervalued.
Does Nyxoah pay dividends?
Nyxoah does not currently pay dividends.
What is Nyxoah’s EPS estimate?
Nyxoah’s EPS estimate is -$0.5.
How many shares outstanding does Nyxoah have?
Nyxoah has 34,360,390 shares outstanding.
What happened to Nyxoah’s price movement after its last earnings report?
Nyxoah reported an EPS of -$0.526 in its last earnings report, missing expectations of -$0.481. Following the earnings report the stock price went down -3.6%.
Which hedge fund is a major shareholder of Nyxoah?
Among the largest hedge funds holding Nyxoah’s share is Iron Triangle Partners LP. It holds Nyxoah’s shares valued at N/A.
---
Nyxoah Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.46 (86.71% Upside)
$15.46 (86.71% Upside)
Blogger Sentiment
Bullish
NYXH Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 253.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
63.90%
12-Months-Change
Fundamentals
Return on Equity
-49.39%
Trailing 12-Months
Asset Growth
11.80%
Trailing 12-Months
Company Description
Nyxoah
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
---
NYXH Earnings Call
Q3 2024
0:00 / 0:00
---
NYXH Stock 12 Month Forecast
Average Price Target
$15.46
▲(86.71% Upside)
Technical Analysis
Best Analysts Covering NYXH
1 Year
1 Year Success Rate
7/14 ratings generated profit
1 Year Average Return
+12.62%
reiterated a buy rating 15 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +12.62% per trade.
---